Offering SPR-BLI Services - Proteins provided for free! Here come GMP Grade Cytokines!Free Sample is available!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
The purity of Human gp130, His Tag (Cat. No. ILT-H52H2) is more than 90% and the molecular weight of this protein is around 85-105kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tocilizumab biosimilar (Livzon Group) | LZM-008 | Approved | Livzon Pharmaceutical Group Inc | 安维泰 | Mainland China | Arthritis, Rheumatoid | Livzon Mabpharm Inc | 2023-01-18 | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (Bio-Thera Solutions) | BAT-1806; BIIB-800 | Approved | Bio-Thera Solutions Ltd | 施瑞立, TOFIDENCE | Mainland China | Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome | Bio-Thera Solutions Ltd | 2023-01-16 | Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Arthritis, Juvenile | Details |
Satralizumab | RG-6168; SA-237 | Approved | Chugai Pharmaceutical Co Ltd | Enspryng, エンスプリング | Japan | Neuromyelitis Optica | Chugai Pharmaceutical Co Ltd | 2020-06-29 | Myasthenia Gravis; Brain Ischemia; Graves Ophthalmopathy; Neuromyelitis Optica; Pulmonary Arterial Hypertension; Encephalitis; Subarachnoid Hemorrhage; Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Details |
Tocilizumab biosimilar (Fresenius kabi) | MSB-11456 | Approved | Merck Serono | EU | Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis | Fresenius Kabi Deutschland Gmbh | 2023-09-15 | Cytokine Release Syndrome; Giant Cell Arteritis; Arthritis, Rheumatoid | Details | |
Tocilizumab | MRA; HPM-1; MRA-SC; R-1569; rhPM-1; RG-1569; RO-48775533 | Approved | Chugai Pharmaceutical Co Ltd | Actemra/RoActemra, 雅美罗, Actemra, RoActemra | Japan | Arthritis, Juvenile; Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD) | null | 2005-04-11 | Uveitis; Respiratory Distress Syndrome, Adult; systemic sclerosis-associated interstitial lung disease; Lupus Erythematosus, Systemic; Coronavirus Infections; Pulmonary Arterial Hypertension; Takayasu Arteritis; Coronary Disease; Multicentric Castleman's Disease (MCD); Breast Neoplasms; Coronaviridae Infections; Fever; Pleural Effusion, Malignant; Pulmonary Disease, Chronic Obstructive; Polymyalgia Rheumatica; Osteoarthritis; Inflammation; Uveitis, Posterior; Lymphoma; Rejection in heart transplantation; Non-ST Elevated Myocardial Infarction; Anemia, Sickle Cell; Kidney Failure, Chronic; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Panuveitis; Carcinoma, Hepatocellular; Myocardial Infarction; Cytokine Release Syndrome; Non-radiographic axial spondyloarthritis; Craniopharyngioma; Motor Neuron Disease; Polymyositis; Diabetes Mellitus, Type 1; Hematologic Neoplasms; Solid tumours; HIV Infections; Polyarticular Juvenile Idiopathic Arthritis; Dermatomyositis; Giant Cell Arteritis; Schnitzler | Details |
Sarilumab | REGN-88; SAR-153191 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | Kevzara | United States | Arthritis, Rheumatoid | Sanofi-Synthelabo | 2017-05-22 | Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Mastocytosis, Systemic; Sarcoidosis; Polymyalgia Rheumatica; Arthritis, Juvenile; Severe Acute Respiratory Syndrome; Uveitis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
VDJ-001 | Phase 2 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) | Details | |
Tocilizumab Biosimilar (qyuns) | QX-003-S | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (Celltrion) | CT-P47; CT-P-47 | Phase 3 Clinical | Celltrion Inc | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (AryoGen Pharmed) | Phase 3 Clinical | Aryogen Biopharma | Arthritis, Rheumatoid | Details | |
Recombinant humanized anti-IL-6R antibody (Hisun Pharma) | HS-628 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
CMAB806 | CMAB-806 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
Levilimab | BCD-089 | Phase 3 Clinical | Biocad | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
Atexakin alfa | SON-080; r-IL-6 | Phase 2 Clinical | Merck Serono, Weizmann Institute Of Science | Peripheral Nervous System Diseases; Diabetic Neuropathies | Details |
Olamkicept | FE-999301; CR-5/18; TJ-301; FE-301 | Phase 2 Clinical | Conaris Research Institute | Colitis, Ulcerative | Details |
This web search service is supported by Google Inc.